This company listing is no longer active
Biohaven Pharmaceutical Holding Past Earnings Performance
Past criteria checks 0/6
Key information
-37.1%
Earnings growth rate
-20.8%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 91.1% |
Return on equity | n/a |
Net Margin | -118.8% |
Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Biohaven Pharmaceutical Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 860 | -1,021 | 862 | 361 |
31 Mar 22 | 738 | -791 | 781 | 361 |
31 Dec 21 | 463 | -847 | 714 | 361 |
30 Sep 21 | 308 | -865 | 616 | 155 |
30 Jun 21 | 190 | -889 | 572 | 131 |
31 Mar 21 | 106 | -859 | 526 | 173 |
31 Dec 20 | 64 | -767 | 462 | 229 |
30 Sep 20 | 29 | -698 | 409 | 222 |
30 Jun 20 | 11 | -609 | 318 | 226 |
31 Mar 20 | 1 | -639 | 217 | 360 |
31 Dec 19 | 0 | -529 | 134 | 345 |
30 Sep 19 | 0 | -434 | 76 | 317 |
30 Jun 19 | 0 | -390 | 54 | 302 |
31 Mar 19 | 0 | -218 | 40 | 155 |
31 Dec 18 | 0 | -241 | 35 | 190 |
30 Sep 18 | 0 | -213 | 30 | 175 |
30 Jun 18 | 0 | -195 | 27 | 162 |
31 Mar 18 | 0 | -202 | 22 | 154 |
31 Dec 17 | 0 | -139 | 18 | 89 |
30 Sep 17 | 0 | -138 | 15 | 87 |
30 Jun 17 | 0 | -123 | 11 | 79 |
31 Mar 17 | 0 | -83 | 8 | 64 |
31 Dec 16 | 0 | -64 | 5 | 56 |
30 Sep 16 | 0 | -42 | 4 | 38 |
Quality Earnings: 2VN is currently unprofitable.
Growing Profit Margin: 2VN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2VN is unprofitable, and losses have increased over the past 5 years at a rate of 37.1% per year.
Accelerating Growth: Unable to compare 2VN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2VN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16.7%).
Return on Equity
High ROE: 2VN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.